Skip to content

Running economy and biomechanics throughout the life cycle of a new shoe: Evaluation during a half-marathon in recreational and trained runners.

Running economy and biomechanics throughout the life cycle of advanced footwear technologies vs. standard footwear: Evaluation during a half-marathon in recreational and trained runners. A parallel group randomised controlled trial.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12625001433493
Enrollment
72
Registered
2025-12-17
Start date
2026-03-16
Completion date
2026-12-01
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Salomon SAS worked on a new kind of advanced footwear technology (AFT) that is not designed with a rigid longitudinal architecture, but rather to optimise foam usage to improve running performance of runners from all levels, and ensure benefit throughout the duration of a running session. This research proposes to compare this new energy (ENER) shoe to a standard and an AFT shoe, assessing benefits during a half-marathon. To do so, participants will be tested for fatigue markers and running biomechanics pre, post, and at different time points during a half-marathon treadmill run. We hypothesise that participating runners will experience a decreasing benefit of AFT, maintained benefits of ENER, and that half-marathon induced neuromuscular fatigue will be lower in AFT and ENER than SFT.

Interventions

Intervention shoe 1: Advanced footwear technology (AFT) running shoe Salomon S/Lab phantasm 3 (Mass: 176 g; Heel stack: 39 mm; Forefoot stack: 33 mm; Drop: 6 mm; Shore Asker C: 38; Foam: polyether block amide). It integrates all required characteristics that define an AFT (i.e., curved longitudinal architecture [mostly through a carbon plate], embedded within a highly resilient, compliant, and lightweight midsole foam). Used in exposures B and C by 1/3 of the participants. Intervention shoe 2:

Intervention shoe 1: Advanced footwear technology (AFT) running shoe Salomon S/Lab phantasm 3 (Mass: 176 g; Heel stack: 39 mm; Forefoot stack: 33 mm; Drop: 6 mm; Shore Asker C: 38; Foam: polyether block amide). It integrates all required characteristics that define an AFT (i.e., curved longitudinal architecture [mostly through a carbon plate], embedded within a highly resilient, compliant, and lightweight midsole foam). Used in exposures B and C by 1/3 of the participants. Intervention shoe 2: Novel advanced footwear technology (ENER) running shoe Salomon prototype (Mass: 290 g; Heel stack: 50 mm; Forefoot stack: 42 mm; Drop: 8 mm; Shore Asker C: 38; Foam: thermoplastic polyurethane). It focuses on foam usage optimisation and shoe geometry, without the use of a rigid longitudinal element. Used in exposures B and C by 1/3 of the participants. Comparator shoe 1: Standard footwear technology (SFT) running shoe Salomon Aero Glide 4 (Mass: 245 g; Heel stack: 38 mm; Forefoot stack: 30 mm; Drop: 8 mm; Shore Asker C: 38; Foam: thermoplastic polyurethane). Used in exposures B and C by 1/3 of the participants. Comparator shoe 2: New version of the shoe participants are attributed to. The shoe model and characteristics are the same as detailed previously for AFT, ENER, or SFT. It will be used for two 6 min treadmill bouts before and after the half-marathon run in exposure C. Exposure A: During a separate preliminary session, participants will complete an incremental treadmill run aiming to determine their maximal aerobic speed. Wearing their own shoes, starting speed will be set depending on participants' 10 km race time. Speed will be increased by 0.5 km/h every minute until voluntary exhaustion. Participants will be randomly attributed to one of the three groups (AFT or ENER or SFT) by the lead investigator (PhD student in sport biomechanics), and will receive the shoe in person. Exposure B: Participants will be instructed to progressively incorporate their attributed shoe (AFT or ENER or SFT) in their running training. Participants will be asked to train with it for 150 km following a progressive running training plan. Training sessions range from 15 min to 120 min, and from 2 to 8 on a rate of perceived exertion scale from 1 to 10. They will train at their usual training place. Adherence to training will be assessed by the lead investigator via weekly questionnaires and sharing of GPS-based running data. Training plan details are available in supporting documents. If participants have their own structured programmes or time constraints that prevent them from implementing the recommended training plan, they can continue using their usual training plans as long as the ratio between use of their allocated shoe and own shoe, and/or weekly running times are respected. Exposure C: After 150 km of training with the shoe, participants will do a half-marathon treadmill run with their allocated shoe at one of the University of Waikato laboratories. Before the half-marathon, participants will run two 6 min bouts with their allocated shoe, two bouts with a new version of their allocated shoe (Comparator shoe 2), and two bouts with the control shoe. After the half-marathon, participants will run two 6 min bouts with a new version of their allocated shoe (Comparator shoe 2) and two bouts with the control shoe. All treadmill runs will be performed at 70% of participants' maximal aerobic speed, except for the half-marathon that will be run at a self-selected race pace, and at 70% of maximal aerobic speed for 6 min intervals every 5 km. Session will be administered and supervised by the lead investigator.

Sponsors

Clément Coulon - The University of Waikato
Lead SponsorIndividual

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

- Be in good general health. - To have been able to run at least 10 km without any lower extremity or lower back problems during the last 6 months (the term ‘problems’ refers to any pain, ache, stiffness, clicking/catching, swelling, instability/giving way, locking or other complaints related to the lower extremities or lower back, other than fatigue-related issues such as cramps or muscle soreness). - Running at least 3h a week on average for the last 6 months. - Over the past year, having a personal best result lower than 4h20 on marathon distance, or 2h05 on half-marathon distance, or 1h on 10k. - Fit the available shoe sizes (7.5 to 13.5 US for female and 6.5 to 12.5 US for male). - Be able to track their running training precisely (e.g. GPS watch, smartphone app). - Have trained with the allocated running shoe for 150 km, more or less 10 km. - To have been able to run at least 10 km continuously with the allocated running shoe. - To give written consent of being confident to use the allocated running shoe to run a half-marathon

Exclusion criteria

- Be currently injured or have been injured in the last 6 months according to the following consensus definition: Running related (training or competition) musculoskeletal pain in the lower limbs or lower back that causes a restriction on or stoppage of running (distance, speed, duration, or training) for at least 7 days or 3 consecutive scheduled training sessions, or that requires the runner to consult a physician or other health professional. - Having previous experience with AFT shoes exceeding 20 km. - Be currently pregnant.

Outcome results

None listed

Source: ANZCTR · Data processed: Mar 14, 2026